New antifungal, isavuconazole, licensed for severe infections

Isavuconazole (Cresemba) can be used to treat patients with invasive aspergillosis and those with mucormycosis when amphotericin B is inappropriate.

by Moriam Adetokunboh-Ajala
Invasive aspergillosis and mucormycosis can now be treated with isavuconazole. | iStock
Invasive aspergillosis and mucormycosis can now be treated with isavuconazole. | iStock

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package